T amoxifen citrate, an oral antiestrogen, is most commonly used in low dosages (20 mg/d) as an adjuvant therapy for breast cancer. At significantly higher dosages (200 mg/d), it has also been used to treat malignant astrocytoma of the brain. 1 Of its welldocumented ocular toxic effects, potentially the most devastating is the development of crystalline maculopathy with associated cystoid macular edema (CME). 2 Treatment consists of cessation of the medication, which may stabilize vision but rarely results in its recovery. We describe the first reported case, to our knowledge, of severe tamoxifen-induced CME resolved with intravitreal bevacizumab (Avastin) therapy.
Report of a Case.
A 37-year-old man had bilateral decreased vision and metamorphopsia. His medical history was significant for anaplastic astrocytoma of the brain diagnosed 13 years earlier, for which he had undergone surgical resection, radiation, and chemotherapy. He had been receiving high-dose tamoxifen citrate (200 mg/d) for the previous 12 years, resulting in a cumulative dose of 876 g. At his initial visit, Snellen visual acuities were 20/60 OD and 20/80 OS. Anterior segment examination findings were unremarkable, without corneal or lenticular opacities. Funduscopic examination revealed extensive bilateral, refractile, white perifoveal crystalline deposits ( Figure, A and B) . Similar refractile deposits were observed in the retinal periphery extending to the ora serrata. Severe CME was noted with bilateral honeycomblike cystic spaces displaying significant late leakage on fluorescein angiography. Optical coherence tomography demonstrated central macular thicknesses of 764 µm OD and 818 µm OS and also confirmed the presence of crystals within the inner retina ( Figure, C and D) .
In coordination with the patient's neuro-oncologist, tamoxifen was discontinued. Seven months later, vision was unimproved and CME was still severe. Both eyes were subsequently treated in staggered fashion with 3 initial intravitreal bevacizumab (1.25 mg) injections at monthly intervals, resulting in marked subjective and objective visual improvement within 2 weeks after the initial injections. Re-treatment at monthly follow-up visits was based on a central macular thickness greater than 250 µm on optical coherence tomography or decreased bestcorrected visual acuity deemed to be secondary to macular edema. 12% in the literature. 2 Toxic effects appear to be dose related, with cumulative doses exceeding 100 g predisposing to vortex keratopathy, lens opacities, optic neuritis, retinal pigment epithelium abnormalities, crystalline maculopathy, and CME. 3 These findings are less commonly seen in patients receiving lower-dose therapy for breast cancer, 2 although the advent of high-resolution spectral-domain optical coherence tomography has revealed more cases of tamoxifen-associated CME in the absence of crystals. 4 The crystalline retinal deposits are classically confined to the nerve fiber and inner plexiform layers and are hypothesized to represent areas of axonal degeneration. 5 Current treatment for tamoxifen maculopathy is discontinuation of the drug. In our case, severe crystalline maculopathy and florid CME were unchanged 7 months after cessation of tamoxifen. Previous experience treating diffuse diabetic macular edema by inhibiting vascular endothelial growth factor, a potent inducer of vascular permeability, with intravitreal bevacizumab prompted us to initiate therapy for this patient. Bourla et al 6 reported improvement of tamoxifen-induced CME with intravitreal pegaptanib sodium (Macugen), but to our knowledge this is the first case of improved tamoxifenassociated crystalline maculopathy and resolved CME with intravitreal bevacizumab therapy.
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Disclosure of Resident Involvement in Ophthalmic Surgery
A n important objective of ophthalmic graduate medical education (GME) is to provide sufficient surgical training to ophthalmology residents so they are competent to enter comprehensive ophthalmic practice. This objective, however, must be balanced with a commitment to provide high-quality patient care, which includes respecting patients' preferences to be informed about the degree of resident involvement in their eye surgery. [1] [2] [3] [4] Currently, the prevalence and details of disclosure policies regarding resident participation and barriers to their implementation in US ophthalmology GME programs are unknown. To help benchmark current practices and assist programs in formulating strategies to implement full disclosure policies, we surveyed US ophthalmology GME program directors (PDs) to determine current practices and policies regarding disclosure of resident involvement in ophthalmic surgery.
Methods. After receiving a study exemption from the Providence VA Medical Center Institutional Review Board, the FREIDA online database (http://www.ama-assn.org /go/freida) was used to identify all ophthalmology GME programs accredited by the Accreditation Council for Graduate Medical Education. Each facility was called to verify the PD's contact information. An anonymous survey including multiple-choice and Likert-style questions ( Table 1 and Table 2 ) was created at http://www .surveymonkey.com. The survey link was sent to all US ophthalmology GME PDs.
Results. One hundred seventeen PDs were surveyed; results are summarized in Table 1 and Table 2 . The response rate was 45.3% (53 of 117 PDs). Fourteen of the 53 PDs (26%) reported that their program had an established policy on disclosing the level of resident involvement in ophthalmic surgery. In programs with an estabFor editorial comment see page 917 
